Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States

Emerg Infect Dis. 2011 Feb;17(2):255-7. doi: 10.3201/eid1702.101724.

Abstract

During April 2009-June 2010, thirty-seven (0.5%) of 6,740 pandemic (H1N1) 2009 viruses submitted to a US surveillance system were oseltamivir resistant. Most patients with oseltamivir-resistant infections were severely immunocompromised (76%) and had received oseltamivir before specimen collection (89%). No evidence was found for community circulation of resistant viruses; only 4 (unlinked) patients had no oseltamivir exposure.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / pharmacology*
  • Child
  • Child, Preschool
  • Drug Resistance, Viral*
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / pharmacology
  • Female
  • Humans
  • Immunocompromised Host
  • Infant
  • Influenza A Virus, H1N1 Subtype / drug effects*
  • Influenza A Virus, H1N1 Subtype / pathogenicity
  • Influenza, Human* / epidemiology
  • Influenza, Human* / mortality
  • Influenza, Human* / physiopathology
  • Influenza, Human* / virology
  • Male
  • Middle Aged
  • Neuraminidase / antagonists & inhibitors
  • Oseltamivir / administration & dosage
  • Oseltamivir / pharmacology*
  • Pandemics*
  • Population Surveillance / methods
  • United States / epidemiology
  • Young Adult

Substances

  • Antiviral Agents
  • Enzyme Inhibitors
  • Oseltamivir
  • Neuraminidase